深度解读！弑母案吴谢宇求谅遭谢天琴家属拒绝 代理律师：已尽力完成辩护工作

弑母案吴谢宇求谅遭谢天琴家属拒绝 代理律师：已尽力完成辩护工作

北京讯（记者 张琳） 2023年11月30日，福州市中级人民法院对吴谢宇弑母案二审宣判，维持原判，判处吴谢宇死刑。据吴谢宇的死刑复核辩护律师郑晓静介绍，吴谢宇在得知二审维持死刑判决后，表现出强烈的求生欲，并多次写信给谢天琴家属道歉，希望能够获得谅解。然而，谢天琴家属并未接受吴谢宇的道歉，并拒绝与其接触。

郑晓静表示，她曾于2023年11月10日前往福州市第一看守所会见吴谢宇。吴谢宇在会见时情绪激动，多次表示后悔杀害了自己的母亲，并希望能够获得家属的谅解。他还表示，愿意将自己名下的两套房产赠送给谢天琴家属，作为对他们造成的伤害的弥补。

郑晓静说，她理解谢天琴家属无法接受吴谢宇道歉的心情。吴谢宇的行为给谢天琴家属造成的伤害无法弥补，他们拒绝与吴谢宇接触也是可以理解的。

郑晓静表示，作为吴谢宇的死刑复核辩护律师，她已经尽力完成了自己的辩护工作。她希望谢天琴家属能够节哀顺变，早日走出伤痛。

以下是对该新闻事件的几点补充:

• 吴谢宇在弑母案发后潜逃三年多，期间曾杀害了一名59岁的出租车司机并抢劫其财物。
• 在二审庭审中，吴谢宇当庭翻供，称自己杀害母亲是受了精神病的影响。
• 法院最终认定，吴谢宇的行为构成故意杀人罪、诈骗罪、买卖身份证件罪，依法判处其死刑。

以下是该新闻事件的几点分析:

• 吴谢宇弑母案是近年来备受关注的重大刑事案件。该案的发生反映出一些家庭教育的缺失和心理问题的严重性。
• 吴谢宇在案发后潜逃三年多，并在逃期间又杀害了一人，性质极其恶劣，罪行累累，受到法律的严惩是理所当然的。
• 谢天琴家属在遭遇如此巨大的创伤后，依然能够保持理智，拒绝与吴谢宇接触，展现了其坚强的意志和高尚的品格。

该新闻事件也引发了社会对以下问题的思考:

• 如何加强家庭教育，预防未成年人犯罪？
• 如何加强对精神疾病患者的管理和治疗？
• 如何完善法律制度，严惩犯罪分子？

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.